Open AccessIn Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections
Author(s) -
Nicole E. Scangarella-Oman,
Karen Ingraham,
Courtney Tiffany,
Lynn P. Tomsho,
Stephanie F. van Horn,
David Mayhew,
Caroline M. Perry,
Theresa C Ashton,
Étienne Dumont,
Jianzhong Huang,
James R. Brown,
Linda A. Miller
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01302-19
Subject(s) - staphylococcus aureus , methicillin resistant staphylococcus aureus , medicine , microbiology and biotechnology , antibiotics , skin infection , biology , bacteria , genetics
A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3 gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h [q8h]) in hospitalized patients with suspected/confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSIs). Evaluating microbiology outcomes and responses were secondary endpoints.